Department of Urology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
Genet Test Mol Biomarkers. 2020 Nov;24(11):692-700. doi: 10.1089/gtmb.2020.0079. Epub 2020 Oct 8.
Circular RNAs (circRNAs), a type of noncoding RNA, are associated with the occurrence and development of cancers. In recent years, their potential as biomarkers for bladder cancer (BC) has attracted increased attention. To reveal the value of circRNAs in the prognosis of BC. Relevant studies were collected to extract the clinicopathological data and overall survival (OS) of patients with BC. We then evaluated their tumor-related clinicopathological indicators using pooled odds ratio (OR) and 95% confidence interval (CI). Hazard ratio (HR) and 95% CI were used to estimate the OS of BC patients who expressed abnormal circRNAs. The results indicate that seven circRNAs (circMYLK, circASXL1, hsa_circ_0000144, circ-VANGL1, circGprc5a, circZFR, and circ-cTFRC) whose expression was upregulated in tumor tissues, are associated with poor clinicopathological features (tumor/node/metastasis [TNM] stage: OR = 4.86, 95% CI: 2.53-9.34; histological grade: OR = 3.71, 95% CI: 2.37-5.79; lymph node metastasis: OR = 3.23; 95% CI: 2.15-4.88; recurrence: OR = 5.33; 95% CI: 2.27-12.52) and poor prognoses (OS: HR = 1.69; 95% CI: 1.17-2.44). We also found that seven circRNAs (circMTO1, circ-ITCH, circUBXN7, circFNDC3B, circ-ZKSCAN1, circPICALM, and circACVR2A) that were downregulated in tumors were associated with better clinicopathological indicators (TNM stage: OR = 0.23, 95% CI: 0.14-0.38; histological grade: OR = 0.21, 95% CI: 0.13-0.33; lymph node metastasis: OR = 0.26; 95% CI: 0.15-0.47) and better prognoses (OS: HR = 0.42; 95% CI: 0.30-0.58). Our results suggest that certain circRNAs are related to the clinicopathological characteristics and prognosis of BC patients, and may potentially be used as biomarkers.
环状 RNA（circRNAs）是一种非编码 RNA，与癌症的发生和发展有关。近年来，其作为膀胱癌（BC）生物标志物的潜力引起了越来越多的关注。为了揭示 circRNAs 在 BC 预后中的价值，我们收集了相关研究，提取了 BC 患者的临床病理数据和总生存期（OS）。然后，我们使用合并的优势比（OR）和 95%置信区间（CI）评估了它们与肿瘤相关的临床病理指标。使用风险比（HR）和 95%CI 估计表达异常 circRNAs 的 BC 患者的 OS。结果表明，七种在肿瘤组织中上调表达的 circRNAs（circMYLK、circASXL1、hsa_circ_0000144、circ-VANGL1、circGprc5a、circZFR 和 circ-cTFRC）与不良临床病理特征（肿瘤/淋巴结/转移[TNM]分期：OR=4.86，95%CI：2.53-9.34；组织学分级：OR=3.71，95%CI：2.37-5.79；淋巴结转移：OR=3.23；95%CI：2.15-4.88；复发：OR=5.33；95%CI：2.27-12.52）和不良预后（OS：HR=1.69；95%CI：1.17-2.44）相关。我们还发现，七种在肿瘤中下调表达的 circRNAs（circMTO1、circ-ITCH、circUBXN7、circFNDC3B、circ-ZKSCAN1、circPICALM 和 circACVR2A）与更好的临床病理指标（TNM 分期：OR=0.23，95%CI：0.14-0.38；组织学分级：OR=0.21，95%CI：0.13-0.33；淋巴结转移：OR=0.26；95%CI：0.15-0.47）和更好的预后（OS：HR=0.42；95%CI：0.30-0.58）相关。我们的结果表明，某些 circRNAs 与 BC 患者的临床病理特征和预后有关，可能具有作为生物标志物的潜力。
